Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

l in patients with solid tumors; - continuing an investigator-sponsored Phase 1 clinical trial evaluating OGX-427 treatment in patients with bladder cancer; - continuing critical path initiatives including manufacturing and clinical trial readiness activities in anticipation of OGX-011 Phase 3 clinical trials; and - meeting working capital needs, capital expenditures and general corporate purposes.

"We have continued to make solid progress in advancing our product pipeline, most recently with the receipt of Fast Track Designation from the U.S. Food & Drug Administration (FDA) for OGX-011 in combination with first-line docetaxel treatment and the initiation of a Phase 1 clinical trial evaluating OGX-427 in patients with bladder cancer," said Scott Cormack, President and CEO of OncoGenex. "We were also able to complete a $9.5 million registered direct offering that, in addition to strengthening our balance sheet and extending our runway, has given us leverage in our effort to secure a development and commercialization partnership for our OGX-011 program and enabled us to commence critical path initiatives including manufacturing and clinical trial readiness activities in anticipation of OGX-011 Phase 3 clinical trials."

"The partnering discussions continue to advance," Cormack added. "In addition to evaluating economic terms, we have been focusing on the level of commitment by potential partners to a development plan for OGX-011. As we are presently drafting definitive agreements, we believe that we are on track to secure a development and commercialization partnership for OGX-011."

It has been widely reported that the Galleon Group is in the process of liquidating all of its funds and winding down its operations. The Galleon Group has verbally confirmed to OncoGenex management that it completed the liquidation of its entire position in OncoGenex on October 20, 2009.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... The following is an open letter sent April ... Blood Corp (NYSE: CO ) from Jayhawk Capital. ... directors of China Cord Blood Corp (" China Cord ") ... share from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, ... benefit Golden Med and Mr. Kam, the Chairman of both ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health science ... SureClinical’s executive team as Chief Financial Officer. ... with over 25 years in leadership roles ranging from ... Morris joins SureClinical from Marrone Bio Innovations (MBI), a ... MBI from its founding in 2006 until 2011, when ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Julie I. Morris Joins SureClinical as Chief Financial Officer 2
... Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... is scheduled to present a company overview at Citi,s 4th ... 1st at 10:40 a.m. EDT.To access the live audio webcast ... . Please connect to Rigel,s website several minutes prior to ...
... of Magnetic Resonance techniques including those used in hospital ... at the University of York. , Ultimately, the technique, ... shuttle, is expected to allow doctors to learn far ... at lower cost while increasing the range of medical ...
... Transform Diabetes CareIRVINE, Calif., March 26 On March ... its prestigious global diabetes research award. The award was ... Diabetes Monitoring Index Test , which uses glycated ... sugar in the body.(Photo: http://www.newscom.com/cgi-bin/prnh/20090326/LA89768 )Diabetes is ...
Cached Biology Technology:Transforming medical diagnosis with new scanning technology 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Greenland ice sheet can experience extreme melting even when temperatures ... Dr. Marco Tedesco, assistant professor in the Department of Earth ... His findings suggest that glaciers could undergo a self-amplifying ... halt. "We are finding that even if you don,t ...
... of us would love nothing more than to trick ourselves into ... a new brain imaging study reported in the November issue of ... just be a way. The key is to go with our ... findings suggest that a simple hormone-inspired pill could be the long-sought ...
... -- With salmonella-tainted ground turkey sickening more than 100 ... ability to detect outbreaks of food-borne illness and determine ... A new approach, reported online Oct. 14 in the ... collaborative team led by Cornell University scientists, will enable ...
Cached Biology News:Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3Simple gut hormone combo makes our brains think we're full 2New test can precisely pinpoint food pathogens 2
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Biology Products: